Skip to Main Content

Paper Details

Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties.
JCI Insight
10
2022
Author NameAffiliation
Jens H KuhnNational Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH)
  • 1 - 1

Datasets

Release 1.2